1 IBS-D is highly prevalent, 2, 3 and it causes low work productivity 4, 5 and low quality of life. 6 Current options are limited for the treatment of IBS-D. 1 Several treatments are proposed, but they all have some disadvantages that limit their use in clinical practice. As initial treatment, dietary and lifestyle modification have variable effects on IBS-D, and their effects are often less than optimal. 7 Alosetron, one of the 5-HT3
antagonists, is effective for abdominal pain and discomfort, but it causes a dose-dependent increase in adverse events (constipation and ischaemic colitis). 8, 9 Rifaximin, an antibiotic treatment, shows promising effect on relieving IBS-D global symptoms. [10] [11] [12] However, questions are raised about potential development of antibiotic resistance in repeated and long-term use of rifaximin. 9, 13 Opioid agonists are reported to be possibly effective for IBS-D, but adverse events related to their use are still a major concern and therefore they are still under investigation. 9, 14 Tong-Xie-Yao-Fang (TXYF) is a Chinese herbal formula for the management of chronic diarrhoea accompanied by abdominal pain; it has been used in China for nearly 600 years. Animal studies showed its efficacy in relieving smooth muscle contraction and decreasing visceral hypersensitivity, [15] [16] [17] and the efficacy may be related to the regulation of 5-hydroxytryptamine and substance P in colonic tissues. 15 Clinical trials showed inconsistent results. A study from Hong Kong found TXYF with little effect on the improvement of IBS-D global symptoms, 18 but a trial from mainland China found it with positive effect. 19 Systematic reviews confirmed the effectiveness of TXYF, 20, 21 but they also concluded the warranty of new trials in this field because of the quality of included trials, the heterogeneity in constituents of TXYF formula, and variety in its clinical effect across the trials.
The objective of our trial is to examine the efficacy of oral administration of TXYF granules (aqueous extract of the TXYF formula that is officially recorded in the Chinese textbook) in the treatment of IBS-D through a placebo-controlled randomised trial.
| ME TH ODS

| Study design
The trial was a double-blind, placebo-controlled randomised trial, Province (Appendix S-A). The trial protocol was registered (clinicaltrials.gov NCT02538692). Before randomisation, the participants were informed that they would receive TXYF treatment or placebo. To examine the credibility of the placebo control, we invited the participants to guess the treatment they received at the end of the study, and we asked them to choose one of the three options: TXYF treatment, placebo or don't know.
| Participants
Patients were included when they met the following criteria: aged between 18 and 75 years; had colonoscopic examinations within 1 year; had a diagnosis of IBS-D based on the Rome III criteria; had abdominal pain ≥2 days in a week; had loose stools (with a Bristol score of 5, 6 or 7) for at least 75% of the time; had a score ≥3 cm measured by visual analog scale (VAS, 10 cm in full length) in global symptoms; had IBS-D symptoms for at least 6 months; had no adequate relief of the IBS-D related symptoms (abdominal pain, bloating, and urgency in evacuation) before randomisation; had a TCM differentiation of liver stagnation and spleen deficiency (Appendix S-B).
Patients were excluded for having at least one of the following conditions: had organic gastrointestinal diseases like colorectal cancer, inflammatory bowel disease, advanced colonic polyp; had gastrointestinal surgery within 1 year; had taken alosetron, tegaserod, lubiprostone, probiotics, rifaximin or antidiarrhoeal drugs within 30 days. Antidepressants (the selective serotonin-reuptake inhibitors or tricyclic antidepressants) were allowed when patients had used one of them for at least 6 weeks, and they managed to keep a stable dose during study period. All the participants provided written informed consents before randomisation.
| Randomisation and masking
Randomisation sequence was generated using stratified block randomisation (with a block of 4 and sex as stratification factor respectively) was extracted in hot water, and the aqueous extract was concentrated, dried, and packed in sealed opaque packages (Appendix S-C). The placebo was with the same appearance as the TXYF granules, and it was made with a mixture of starch, lactose (<1% by weight), food colourants, and bitterants. Participants were asked to dissolve the granules by hot water and drink the mixture.
Concomitant treatments for IBS-D were not allowed during the study period, including alosetron, tegaserod, lubiprostone, probiotics, rifaximin or antidiarrhoeal drugs.
| Outcomes
Participants were asked to record daily diaries. The diaries included Outcome assessors collected the data from the diaries, and two independent assistants entered them into electronic case report forms. A statistician checked completeness and accuracy of the data and prepared them for analysis.
| Statistical analysis
On the basis of a previously published trial, 18 we assumed the rate of participants with adequate relief of global IBS-D symptoms to be 50% after TXYF treatment, and a difference of 20% compared with placebo (the rate of adequate relief was anticipated to be 30%) was considered as clinically relevant. 14 Assuming a significant level of 0.05, a power of 0.8, and a coefficient representing the correlation among covariates of 0.3, we needed a total of 146 participants. Considering a dropout rate of 10%, we needed a total sample size of 160.
The statistical analysis plan was shown in Appendix S-D. All analyses were based on intention-to-treat (ITT) population, which was defined as all participants who were randomised to treatment, received at least one treatment session, and had at least one assessment on the primary outcome. Analyses based on per-protocol (PP analysis) population were performed as supportive statistics. Missing values were filled in using the last-observation-carried-forward method.
Numbers and percentages were calculated for binary data; means and standard deviations (SD) were calculated for continuous outcomes. We used odds ratio (OR) and mean difference (MD) to describe the effect size of TXYF granules in contrast to placebo, and the relative corresponding 95% CIs were provided.
Difference in the primary outcome was detected using the Chisquare test, and it was further confirm using a logistic regression model with the study group as random-effect variable and with age, duration of IBS-D, and the number of doses administered as covariates in the model. Adequate relief assessed on the weekly basis was compared between groups using the same logistic regression model.
Between-group differences in the mean weekly VAS scores of global symptoms and major IBS-D symptoms, weekly stool frequency, and weekly Bristol score were examined using general linear model (GLM), in which we fitted the same covariates as the logistic regression model. The proportion of adverse events was compared between groups with the Chi-square test. All statistical analyses were two sided, and P < 0.05 was recognised as existence of statistically significant difference.
| RESULTS
| Trial characteristics and credibility test
From December 2015 to February 2017, 316 patients with suspected IBS-D were screened for eligibility ( Figure 1) ; 160 of them were enrolled and randomly allocated (142 were from Chengdu center, and 18 were from Luzhou center). All participants received the treatment that they were assigned, and 155 participants received at least 80% of the total doses. All participants received safety assessments. The ITT population included 160 participants; the PP population included 155 participants.
The ITT population showed an average age of 34 years, and it showed a mean VAS score of 7.1 cm in IBS-D global symptoms, 4.9 cm in abdominal pain and 5.2 cm in bloating respectively ( do not know. The credibility showed that blinding was successful (v 2 = 0, P = 1.000).
| Adequate relief of global IBS-D symptoms
The rate of participants achieving the primary outcome was signif- Figure 2 shows the change in the rate of weekly adequate relief from week 1 to week 12, and Figure S1 shows the effect size of TXYF in each weekly assessment.
Significant between-group difference was observed from week 3 (41.3% vs 25%, OR 2.2, 95% CI 1.1-4.6, P = 0.03) to week 7 (38.8% vs 21.3%, OR 2.2, 95% CI 1.1-4.7, P = 0.03).
Analyses based on the worst-case method showed similar results.
| VAS scores of global symptoms and major symptoms
At week 3, participants in TXYF group started to have significantly lower VAS score of global symptoms than those in the placebo group (3.3 AE 1.1 vs 4.4 AE 1.5 cm; MD, À1.2 cm; 95% CI, À1.7-À 0.7; P < 0.001; Figure 3A) ; at week 7, the difference between the two groups was still significant (4.0 AE 1.2 vs 4.8 AE 1.6 cm; MD, À0.8 cm; 95% CI, À1.20-À0.4; P = 0.02). GLM model found that age, duration of IBS-D, and the number of doses administered had no effect on the VAS scores.
TXYF granules had similar effects on the VAS scores of abdominal pain, bloating, and tiredness as on the VAS score of global symptoms. TXYF showed superiority over placebo in abdominal pain from week 3 (3.3 AE 1.0 vs 4.1 AE 1.1 cm; MD, À0.8 cm; 95% CI, À1.0-À0.6; P < 0.001; Figure 3B ) to week 12 (3.1 AE 0.8 versus 4.2 AE 0.9 cm; MD, À1.1 cm; 95% CI, À1.4-À 0.8; P < 0.001). TXYF had similar effect on bloating as on abdominal pain ( Figure 3C ). TXYF caused lower VAS score in tiredness than did placebo from week 2 (3.4 AE 1.1 vs 3.9 AE 1.3 cm; MD, À0.5 cm; 95% CI, À0.9-À0.1; P = 0.01; Figure 3E ) to week 6 (2.9 AE 1.0 vs 3.2 AE 1.0 cm; MD, À0.3 cm; 95% CI, À0.6-0; P = 0.007). Figure S2 shows the effect size of TXYF in each outcome assessment. However, TXYF was inefficacious in relieving urgency ( Figure 3D ). Analyses of the above outcomes based on PP population showed similar results. Significantly lower Bristol score in TXYF group was observed at week 2 than in the placebo group (5.3 AE 0.7 versus 5.6 AE 0.7; MD, À0.3; 95% CI, À0.5-À0.1; P = 0.02; Figure 3G ), and the effect also lasted to week 12 (4.7 AE 0.8 versus 5.7 AE 0.8; MD, À1.0; 95% CI, À1.3-À0.7; P < 0.001). Figure 2s shows the effect size of TXYF on stool frequency and Bristol score. Analyses based on PP population showed similar results.
| Stool frequency and Bristol score
| Adverse events
Three (3.8%) adverse events in TXYF group were reported; one (1.3%) was constipation (relieved after we suggested increase in fibre intake), one (1.3%) was elevation in liver-enzyme (returned to normal at the end of follow-up); and one (1.3%) was nausea after treatment (disappeared after we stopped treatment for one day). Three (3.8%)
adverse events in placebo group were reported. One (1.3%) was abdominal distension (disappeared after evacuation); two (2.5%)
were nausea (disappeared after we stopped treatment for 1 day).
Between-group difference was not significant in the rate of adverse events (v 2 = 0, P = 1.000).
| DISCUSSION
Whether TXYF should be recommended to patients with IBS-D was controversial because of the lack of evidence and conflict findings from previous trials. Our study found that TXYF is significantly superior to placebo in the improvement of IBS-D global symptoms, abdominal pain and bloating. A 4-week treatment with TXYF caused a relief of these symptoms for 6-8 weeks, and a low rate of adverse events was found.
A major concern in evaluating the effect of TXYF is the heterogeneity in gradients of the prescription in previous trials. A systematic review included 12 trials evaluating the effect of TXYF on IBS;
it found that 11 of the 12 trials used modified TXYF prescriptions. 20 The investigators of the 11 trials added herbs to the standard TXYF formula according to their own experience. The variety in the prescriptions of TXYF caused significant heterogeneity in clinical effects.
After the publication of the review, two trials with relatively sufficient power were conducted; 18, 19 and these two trials still used different TXYF prescriptions. One of the trials from Hong Kong According to recent reviews 1, 9 and randomised controlled trials 10, 11, 14, 24, 25 assessing other interventions for IBS, evaluation of the global symptoms should be used as the first choice, and other measures for abdominal pain, bloating and diarrhoea should be used as secondary outcomes.
The third major concern was the treatment duration of TXYF granules. According to a systematic review included 12 trials evaluating the effectiveness of TXYF decoction, 20 seven of the 12 trials adopted a treatment duration of 4 weeks, two adopted a flexible treatment duration from 4-6 weeks, and one adopted a duration from 2-4 weeks. Based on this review and Pan's trial, 19 we decided the treatment duration as 4 weeks in this trial, and it was agreed in an expert consensus meeting before the trial was carried out. In addition, we chose a follow-up period of 8 weeks to observe the persistent effect of TXYF granules, since a systematic review 20 showed that TXYF decoction was superior to conventional treatments in both short-term (3 months after discontinuing treatment) and long-term period (over 6 months after discontinuing treatment).
We noticed a prolonged effect of TXYF in most of the secondary outcomes, which was also found in a systematic review. 20 The prolonged effect of TXYF may be the consequence of regulation of the brain-gut axis. This assumption was supported by our experimental research showing that TXYF regulated the secretion of BDNF in both the hippocampus and the myenteric nerve plexus, and the change in BDNF secretion was correlated with decreased visceral hypersensitivity and hyperactive intestinal motility in rats with IBS-D. 26 The difference between TXYF granules and placebo in major IBS-D symptoms seemed to be significantly widened after treatment for 2 weeks instead of after initiation of treatment. Although the exact mechanism is unknown, we have several assumptions. First, placebo effect on IBS-D symptoms reached its peak in the first 2 weeks, while the effect of TXYF still increased over time. A review by Spiller showed that the placebo effect could drop to 20% or below when a trial duration of IBS was longer than 12 weeks 27 and that a longer study period was associated with lower placebo response. A meta-analysis by Ford and colleagues showed similar results. 28 Second, TXYF might work mainly through regulation of the gut microbiota, which needs accumulation of treatment to achieve.
Rifaximin showed similar changes in response rates when compared with placebo. 10, 11, 13 However, this assumption needs further study to confirm. Third, the lactose in placebo may decrease the placebo effect, although a low level of lactose (<1%) was shown unrelated to deterioration of IBS-D symptoms. 18 Placebo control is essential for evaluating the actual effect of herbal medicine. Most of the previous trials used water-decoctum, 20 which was prepared by boiling raw herbs directly. Water-decoctum preparations are difficult to simulate in appearance and flavour, therefore, the previous trials often used conventional treatment as control. 19, 20 In our study, we used granules that was prepared with aqueous extracts from raw herbs, and the TXYF granules were sealed in packages with the same appearance as the placebo. The credibility test showed that the design achieved successful blinding throughout the study period. We found that 63.2% of the participants receiving TXYF versus 57.3% of the participants receiving placebo assumed that they received TXYF granules. The reason might be that the appearance and the flavour of TXYF or placebo were similar to traditional herbal medicine and that most of the participants without enough experience to tell the difference (only 0.2% of the participants with experience of using TXYF decoction).
One advantage in using TXYF to treat patients with IBS-D is the low rate of adverse events. Our study found it consistent with the findings of previous trials. 18, 19 However, our trial found one participant with liver-enzyme elevation after treatment. It is uncertain whether the elevation in liver-enzyme was caused by TXYF, since previous trials did not report similar side effects. Therefore, observational studies with large sample size are needed to evaluate the safety of TXYF.
Our study has several limitations. First, the placebo control still needs improvement. The flavour of the placebo was not exactly identical to TXYF. It still had the risk of unblinding, although the chance is low. Second, a fixed dose was used in our study as in the previous trials. However, the dose of TXYF will be adjusted according to patients' symptoms in actual clinical practice (eg we will add the dose of Bai Shao and Fang Feng when a patient presents mainly with the symptoms of abdominal pain and urgency).
In future studies, a more real-world treatment protocol should be introduced.
| CONCLUSION
TXYF is efficacious in relieving global IBS-D symptoms, abdominal pain and bloating with a low rate of adverse events. Future studies are warranted to further clarify the elevation in hepatic enzyme.
